Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

BioStem Technologies, Inc. Announces the Engagement of Investment Banking Firm Young America Capital for 15 Million Dollar 506(c) Offering.


Posted on: 26 Jan 18

Pompano Beach, FL, Jan. 26, 2018 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC PINK: BSEM) (“BSEM” or “Company”) announced today the engagement of investment banking firm Young America Capital as an advisor for the Company’s upcoming 15 Million dollar, Reg D, 506(c) private placement offering.

“Over the past year, BioStem Tech has made impressive progress with the completion of our state of the art biotech lab and the launch of our pharmaceutical division” said Henry Van Vurst, the Company’s CEO. “Given that progress, we believe that the time is right to engage an award winning investment banking advisory firm to help us secure the growth capital we need for the next stage of the Company’s development; and YAC’s track record in growth capital funding speaks for itself.”

The $15 million offering will be open not only to individual accredited investors, but also to qualified institutional buyers (“QIB’s”) through YAC, under Rule 144(a) safe harbor, which permits QIBs to trade such securities among themselves. “The exciting thing about this is that as we prepare to uplist to the QX we will also move upstream to institutional buyers for our corporate financing needs”, said Mr. Van Vurst. 

Peter Formanek, Managing Partner said “We’re very pleased to be advising BioStem Technologies, Inc. in this offering. We think the time is right for the convergence of pharmaceuticals and regenerative medicine and we believe that BioStem is pursuing a winning strategy. This offering is an excellent opportunity for our qualified institutional buyers to participate with BioStem at the earliest stage of what we believe will be impressive rapid growth performance.”

About BioStem Technologies, Inc. (OTC PINK: BSEM): BioStem Technologies, Inc. is a global life sciences corporation, providing innovative technologies with a concentration in Pharmaceuticals and Regenerative Medicine. The Company’s mission is to discover, develop and produce the most effective Pharmaceutical and Regenerative Medicine products in the world. The Company is comprised of a diverse group of scientists, physicians and entrepreneurs who collaborate to create innovative products. These technologies improve the Quality of Life for our patients and, as a result, drive shareholder value. www.biostemtech.com

About Young America Capital, LLC

Founded in 2000, Young America Capital is a New York-based FINRA/SEC/MSRB licensed independent investment banking and advisory firm which provides capital raising, M&A advisory and fund marketing services for companies and alternative investment fund managers. The company is comprised of a diverse group of senior investment banking professionals with particularly deep sector experience in Consumer & Retail, Energy & Clean-Tech, Technology, Media and Telecom, Healthcare & Life Sciences; Maritime, Infrastructure & Logistics, Financial Services & Fin-Tech, Real Estate, and Latin America. www.yacapital.com

Forward-Looking Statements: Except for statements of historical fact, the matters discussed in this press release are forward looking and made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "future," "plan" or "planned," "expects," believe" or "projected." These forward-looking statements reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond the company's control that may cause actual results to differ materially from stated expectations. These risk factors include, among others, limited operating history, difficulty in developing, exploiting and protecting proprietary technologies, intense competition and additional risks factors as discussed in reports filed by the company with OTC Markets.

CONTACT: BioStem Technologies, Inc. Phone: 954-380-8342 Website: http://www.biostemtech.com Email: info@biostemtech.com Twitter: @Biostemtech Facebook: BioStem Technologies Investor Relations: Andrew Van Vurst info@biostemtech.com (954) 380-8342GlobeNewswire
globenewswire.com

Last updated on: 29/01/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.